When not working or writing, Hugo can be found consuming copious amounts of anime and manga ... weight loss behaviors with interest in GLP-1 medications for weight loss. Conversely, body ...

A new study from Rutgers University links higher body dissatisfaction, BMI, and maladaptive weight loss behaviors with ...

Another benefit of GLP-1 receptor agonist (RA) use may be protection from persistent atrial fibrillation (Afib or AF) after ablation, according to a large Veterans Affairs database. New initiators ...

Glucagon-like peptide 1 receptor agonists (GLP-1 RAs) continue to skyrocket in popularity as both approved and off-label treatments for weight loss. However, their widespread use raises ...

So-called GLP-1 supplements, named to echo the class of glucagon-like peptide-1 agonist drugs that includes Wegovy and Zepbound, are likely to be ineffective for weight loss. “If you can buy it ...

This study found that using GLP-1 RAs and SGLT2is for type 2 diabetes treatment offers potential neuroprotections against Alzheimer disease and related dementias. HealthDay News — Both glucagon ...

An oral version of these drugs—which are known as glucagon-like peptide 1 (GLP-1) receptor agonists—could be more accessible and would come without the inconvenience, pain or medical waste of ...

Use of GLP-1 receptor agonists was associated with improved survival and reduced graft loss among kidney transplant recipients with type 2 diabetes. Glucagon-like peptide-1 (GLP-1) receptor ...

Called orforglipron, the results of a new clinical trial announced Thursday by manufacturer Eli Lilly suggest that the pill could be a breakthrough in a class of drugs called GLP-1 agonists ...

Patients using GLP-1 receptor agonists appear to have a lower risk of age-related macular degeneration and primary open-angle glaucoma. Glucagon-like peptide 1 receptor agonists (GLP-1 RAs ...

The rise of GLP-1 weight loss drugs represents a shift in the way consumers approach their health goals The rise of GLP-1 drugs for weight loss represents a remarkable shift in the way people ...

However, emerging research suggests that glucagon-like peptide-1 (GLP-1) receptor agonists—commonly used in treating type 2 diabetes and obesity—may offer new promise in treating AUD.